YU55603A - Derivati purina kao antagonisti purinergiskog receptora - Google Patents

Derivati purina kao antagonisti purinergiskog receptora

Info

Publication number
YU55603A
YU55603A YU55603A YUP55603A YU55603A YU 55603 A YU55603 A YU 55603A YU 55603 A YU55603 A YU 55603A YU P55603 A YUP55603 A YU P55603A YU 55603 A YU55603 A YU 55603A
Authority
YU
Yugoslavia
Prior art keywords
alkyl
aryl
disorder
group
linked
Prior art date
Application number
YU55603A
Other languages
English (en)
Inventor
Roger John Gillespie
Joanne Lerpiniere
Claire Elizabeth Dawson
Suneel Gaur
Robert Mark Pratt
Gemma Caroline Stratton
Scott Murray Weiss
Original Assignee
Vernalis Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Research Limited filed Critical Vernalis Research Limited
Publication of YU55603A publication Critical patent/YU55603A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Upotreba jednog jedinjenja formule (I): gde R1 se bira od alkila, arila, alkoksi, ariloksi, tioalkila, tioarila, CN, halo, NR5R6, NR5SOR5, NR4CONR5R6, NR4CO2R7 i NR4SO2R7; R2 se bira od heteroarilnih grupa koje sadrze N, O ili S, pri cemu je heteroarilna grupa vezana preko jednog nezasicenog ugljenikovog atoma koji je susedan jednom ili dvoma N, O ili S, heteroatomima, koje nisu orto, orto-dvostruko supstituisane heteroarilne grupe; R3 se bira od H, alkila, COR8, CONR9R10, CONR8NR9R10, CO2R11 i SO2R11; R4, R5 i R6 biraju se nezavisno od H, alkila i arila, ili kada su R5 i R6 u jednoj (NR5R6) grupi, R5 i R6 mogu biti vezani da obrazuju jedan heterociklicni prsten; a R7 se bira od alkila i arila; R8, R9 i R10 nezavisno se biraju od H, alkila i arila, ili R9 i R10 mogu biti povezani da obrazuju jedan heterociklicni prsten, ili kada su R8, R9 i R10 u jednoj (CONR8NR9R10) grupi, R8 i R9 mogu biti povezani da obrazuju jednu heterociklicnu grupi, a R11 se bira od alkila i arila, ili neke nejgove farmaceutski prihvatljive soli ili nekog njegovog porleka, za lecenje ili sprecavanje nekog poremecaja gde bi blokiranje purinskih receptora, posebno adenozinskih receptora, a narocito A2A receptora, moglo biti delotvorno, posebno kada je taj poremecaj jedan poremecaj kretanja kao sto je Parkinsonova bolest, ili je poremecaj depresija, ostecenje spoznaje ili pamcenja, akutni ii hronini bol, ADHD ili sindrom pospanosti, ili za neurozastitu kod nekog subjekta; jedinjenja formule (I) za koriscenje u terapiji, i nova jedinjenje formule (I) sama po sebi.
YU55603A 2001-01-10 2002-01-10 Derivati purina kao antagonisti purinergiskog receptora YU55603A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0100623.8A GB0100623D0 (en) 2001-01-10 2001-01-10 Chemical compounds IV

Publications (1)

Publication Number Publication Date
YU55603A true YU55603A (sh) 2006-05-25

Family

ID=9906570

Family Applications (1)

Application Number Title Priority Date Filing Date
YU55603A YU55603A (sh) 2001-01-10 2002-01-10 Derivati purina kao antagonisti purinergiskog receptora

Country Status (22)

Country Link
US (2) US7452894B2 (sh)
EP (1) EP1349857B1 (sh)
JP (1) JP4284069B2 (sh)
KR (1) KR20030079945A (sh)
CN (1) CN1617871A (sh)
AT (1) ATE471323T1 (sh)
AU (1) AU2002217331B2 (sh)
BR (1) BR0206561A (sh)
CA (1) CA2433858C (sh)
CZ (1) CZ20031956A3 (sh)
DE (1) DE60236719D1 (sh)
GB (1) GB0100623D0 (sh)
HU (1) HUP0402504A2 (sh)
IL (1) IL156779A0 (sh)
MX (1) MXPA03006163A (sh)
NO (1) NO20033145L (sh)
NZ (1) NZ527249A (sh)
PL (1) PL363172A1 (sh)
RU (1) RU2003124653A (sh)
WO (1) WO2002055521A1 (sh)
YU (1) YU55603A (sh)
ZA (1) ZA200305116B (sh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081472A1 (fr) * 2001-04-05 2002-10-17 Sumika Fine Chemicals Co., Ltd. Procede de production de 2,6-dihalogenopurine
AU2002343604C1 (en) 2001-10-30 2009-09-17 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
DE10252650A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Cyclohexyl-Harnstoff-Derivate
NZ546611A (en) * 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
WO2005085210A1 (ja) * 2004-03-10 2005-09-15 Ono Pharmaceutical Co., Ltd. ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US20090023723A1 (en) * 2005-09-21 2009-01-22 Pharmacopeia Drug Discovery, Inc. Purinone derivatives for treating neurodegenerative diseases
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7919490B2 (en) 2006-10-04 2011-04-05 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
WO2008043019A1 (en) 2006-10-04 2008-04-10 Pharmacopeia, Inc 8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
KR101701109B1 (ko) * 2007-10-05 2017-02-13 베라스템, 인코포레이티드 피리미딘 치환된 퓨린 유도체
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
EP2414362B1 (en) 2009-04-03 2014-06-11 Verastem, Inc. Pyrimidine substituted purine compounds as kinase (s) inhibitors
ES2880291T3 (es) 2011-06-02 2021-11-24 Univ Louisville Res Found Inc Nanopartículas conjugadas a un agente antinucleolina
WO2012172043A1 (en) * 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
KR20140145171A (ko) * 2012-04-17 2014-12-22 아스테라스 세이야쿠 가부시키가이샤 함질소 이환식 방향족 헤테로환 화합물
CA3039483C (en) * 2016-11-18 2021-05-04 The Procter & Gamble Company Fabric treatment compositions and methods for providing a benefit
US10870816B2 (en) 2016-11-18 2020-12-22 The Procter & Gamble Company Fabric treatment compositions having low calculated cationic charge density polymers and fabric softening actives and methods for providing a benefit
JP7137225B2 (ja) * 2017-08-21 2022-09-14 国立大学法人三重大学 非ヒト哺乳類の脳梗塞モデルによる観察方法及び非ヒト哺乳類の脳梗塞モデルによる観察装置
CN107903274A (zh) * 2017-12-28 2018-04-13 窦玉玲 一种胺类化合物及其在抗肿瘤药物中的应用
US20220380310A1 (en) * 2019-07-01 2022-12-01 Ligang Qian P2x7r antagonists
KR20210061202A (ko) * 2019-11-19 2021-05-27 일동제약(주) 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
US11806350B2 (en) 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3630997A (en) * 1970-05-04 1971-12-28 Paul M Craven Curable epoxy resin compositions and method of preparing same
US5064745A (en) * 1988-02-25 1991-11-12 Mitsubishi Paper Mills, Ltd. Method for making lithographic printing plate
US5403932A (en) * 1988-05-25 1995-04-04 Research Corporation Technologies, Inc. Phosphoramidates useful as antitumor agents
US5968989A (en) * 1991-12-18 1999-10-19 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
DE4330735A1 (de) * 1993-09-10 1995-03-16 Wacker Chemie Gmbh Hydrophile Gruppen aufweisende Organopolysiloxane
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
AU746706B2 (en) 1997-07-03 2002-05-02 Du Pont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
WO1999026627A1 (en) 1997-11-26 1999-06-03 Cerebrus Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
CA2315736A1 (en) 1998-01-05 1999-07-15 Eisai Co., Ltd. Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus
JPH11279193A (ja) * 1998-03-24 1999-10-12 Akira Matsuda アデノシン誘導体
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
WO2001002400A1 (fr) * 1999-07-02 2001-01-11 Eisai Co., Ltd. Composes imidazole fusionnes et medicaments contre le diabete sucre
KR20020093950A (ko) * 2000-04-26 2002-12-16 워너-램버트 캄파니 아형 선택적인 ｎｍｄａ 수용체 길항제로서의시클로헥실아민 유도체
US6903238B2 (en) * 2001-12-13 2005-06-07 Wyeth Substituted indenones as estrogenic agents
US6946005B2 (en) * 2002-03-27 2005-09-20 L'oreal S.A. Pyrrolidinyl-substituted para-phenylenediamine derivatives substituted with a cationic radical, and use of these derivatives for dyeing keratin fibers
DE10326303A1 (de) * 2003-06-11 2004-12-30 Celares Gmbh Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung
CN101103026A (zh) * 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
ATE510846T1 (de) * 2005-09-09 2011-06-15 Boehringer Ingelheim Int Cyclisierendes metatheseverfahren zur herstellung von makrocyclischen peptiden
ES2335360T3 (es) * 2005-11-25 2010-03-25 Galapagos Sas Derivados de urea utiles como moduladores de los receptores de calcio.
US8143236B2 (en) * 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
KR20090029827A (ko) * 2006-07-20 2009-03-23 제네랩스 테크놀로지스, 인코포레이티드 폴리사이클릭 바이러스 억제제

Also Published As

Publication number Publication date
US20040102459A1 (en) 2004-05-27
GB0100623D0 (en) 2001-02-21
CA2433858A1 (en) 2002-07-18
NO20033145L (no) 2003-09-09
HUP0402504A2 (hu) 2005-04-28
PL363172A1 (en) 2004-11-15
ATE471323T1 (de) 2010-07-15
NO20033145D0 (no) 2003-07-09
CZ20031956A3 (cs) 2003-11-12
US7452894B2 (en) 2008-11-18
ZA200305116B (en) 2004-07-01
WO2002055521A1 (en) 2002-07-18
DE60236719D1 (de) 2010-07-29
CA2433858C (en) 2010-12-14
MXPA03006163A (es) 2003-09-16
EP1349857A1 (en) 2003-10-08
KR20030079945A (ko) 2003-10-10
EP1349857B1 (en) 2010-06-16
US20060270691A1 (en) 2006-11-30
RU2003124653A (ru) 2005-01-10
JP2004517874A (ja) 2004-06-17
JP4284069B2 (ja) 2009-06-24
IL156779A0 (en) 2004-02-08
BR0206561A (pt) 2004-06-22
NZ527249A (en) 2005-04-29
AU2002217331B2 (en) 2006-06-29
CN1617871A (zh) 2005-05-18

Similar Documents

Publication Publication Date Title
YU55603A (sh) Derivati purina kao antagonisti purinergiskog receptora
DK1392312T3 (da) Triazolo-4,5 d-pyrimidinderivater og anvendelse deraf som purinerge receptorantagonister
DE60228414D1 (de) Pyrrolo 2,3-d pyrimidine und deren verwendung als purinreceptor antagonisten
HK1068334A1 (en) Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
DE60228817D1 (de) THIENO(3,2-d)PYRIMIDINE UND FURANO(3,2-d)PYRIMIDINE UND DEREN VERWENDUNG ALS ANTAGONISTEN AN PURINERGEN REZEPTOREN
MXPA02012166A (es) Derivados de azaindol, proceso para su preparacion y su uso como agentes antitumor.
PE20020104A1 (es) Derivados de benzotiazol
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
DK1107973T3 (da) Hidtil ukendte thieno(2,3-D)pyrimidindioner, fremgangsmåde til deres fremstilling og anvendelse deraf i terapi
TW200503712A (en) (2-carboxamido)(3-amino)thiophene compounds
IL179171A0 (en) Alkyl substituted indoloquinoxalines
MXPA04000407A (es) Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales.
NZ515407A (en) 4-Phenyl-pyrimidine derivatives